• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Eli Lilly and Company

    7/24/25 3:01:36 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0000316011
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ELI LILLY AND CO
    SEC File Number
    001-06351
    Address of Issuer
    LILLY CORPORATE CTR
    DROP CODE 1094
    INDIANAPOLIS
    INDIANA
    46285
    Phone
    3172762000
    Name of Person for Whose Account the Securities are To Be Sold
    LILLY ENDOWMENT INC
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Fidelity Capital Markets
    640 Fifth Avenue
    New York � NY � 10019
    28000022368920094773565107/24/2025
    NYSE, NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock02/10/1948GiftJ.K. Lilly Sr. TrustCheckbox checked01/21/193738400000N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/24/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Diane M. Stenson, Vice President & Treasurer

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 31, 2024 - FDA Roundup: May 31, 2024

      For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

      5/31/24 3:22:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 7, 2024 - FDA Roundup: May 7, 2024

      For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

      5/7/24 4:10:24 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 5, 2023 - FDA Roundup: December 5, 2023

      For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

      12/5/23 5:00:21 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

      INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (NASDAQ:VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines

      7/25/25 8:49:00 AM ET
      $LLY
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease

      The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers. The European Commission is expected to make a regulatory decision on donanemab in the coming months. "This positive opinion marks a significant milestone in our efforts to bring donane

      7/25/25 6:27:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly confirms date and conference call for second-quarter 2025 financial results announcement

      INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into hea

      7/24/25 10:00:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eli Lilly downgraded by Erste Group

      Erste Group downgraded Eli Lilly from Buy to Hold

      6/5/25 7:52:21 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Eli Lilly from Buy to Reduce and set a new price target of $700.00 from $1,150.00 previously

      4/28/25 8:33:23 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Eli Lilly with a new price target

      Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00

      4/22/25 7:32:42 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lilly Endowment Inc sold $225,419,259 worth of shares (280,000 units at $805.07), decreasing direct ownership by 0.29% to 95,736,978 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      7/25/25 4:00:06 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Luciano Juan R was granted 19 shares, increasing direct ownership by 0.12% to 16,382 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      7/22/25 5:27:47 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sulzberger Gabrielle was granted 7 shares, increasing direct ownership by 0.25% to 2,586 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      7/22/25 4:55:32 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    SEC Filings

    See more
    • SEC Form 144 filed by Eli Lilly and Company

      144 - ELI LILLY & Co (0000059478) (Subject)

      7/24/25 3:01:36 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Eli Lilly and Company

      11-K - ELI LILLY & Co (0000059478) (Filer)

      6/20/25 4:23:15 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Eli Lilly and Company

      SD - ELI LILLY & Co (0000059478) (Filer)

      5/9/25 4:12:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

      Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

      11/13/24 9:30:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly appoints Lucas Montarce as executive vice president and chief financial officer

      INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

      9/9/24 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Financials

    Live finance-specific insights

    See more
    • Lilly confirms date and conference call for second-quarter 2025 financial results announcement

      INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into hea

      7/24/25 10:00:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares second-quarter 2025 dividend

      INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

      5/5/25 12:47:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      10/23/24 5:17:34 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      2/13/24 5:04:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      1/26/24 4:25:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care